

Publications List

1. Wong, J.P., Viswanathan, S., Wang, M, Sun, L.Q., Clark, G. and D'Elia R. Current and future developments in the treatment of virus-induced hypercytokinemia. *Future Med. Chem.* 9(2): (2017). (DOI: 10.4155/fmc-2016-0181)
2. Hu, Y., Hu, Y., Sun L., Wong J., Wang, M. Antiviral effects of liposome-encapsulated Poly(ILEC) against dengue virus in a mouse model. *Biochem. Biophys. Res. Comm.* 478(2):913-918 (2016)
3. Sun, LQ and Wong, J.P. Frontiers in nucleic acid-based drug research and development. *Future Med. Chem.* 7(13): 1619-1621 (2015)
4. Wong, J.P., DiTullio, P and S Parkinson. Bisphosphocins: Novel Antimicrobials for enhanced killing of drug-resistant and biofilm-forming bacteria. *Future Microbiology* 10(11):1751-1758 (2015)
5. Wong, J.P. Nucleic acid-based drugs against emerging zoonotic viruses. *Future Med. Chemistry* 7(13): 1709-1720 (2015) (DOI: 10.4155/fmc.15.112).
6. Wong, J.P. Experimental antiviral drugs against pandemic influenza. *Future Virology* 10(5):597-607, 2015.
7. Wong, J.P. Confronting the emerging threats from zoonotic and mosquito-borne viruses. *Future Virology* 10(5): 465-468, 2015.
8. Xie, J., Zhang, S., Hu, Y., Li, Y., Cui, D., Xue, J., Zhang, G., Khachigian, L.M., Wong, J., Sun, L and M. Wang. Regulatory roles of c-jun in H5N1 influenza virus replication and host inflammation. *Biochimica et Biophysica Acta* 1842:2479-2488, 2014
9. Wong, J.P. and A.M. Salazar. Nucleic acid-based drugs for eliciting host's innate immunity against viral diseases. *In: Nucleic Acid-based Drugs* (J.P. Wong, ed.):102-104, 2013, Future Medicine Ltd, London, England.
10. Wong, J.P. Nucleic acid-based drugs: Foreword. *In: Nucleic Acid-based Drugs* (J.P. Wong, ed.):102-104, 2013, Future Medicine Ltd, London, England.
11. Nagata, L.P., Wong, J.P., Hu, W-H. and J.Q. Wu. Vaccines and therapeutics for encephalitic alphaviruses. *Future Virology* 8(7):661-677, 2013.

12. Hamblin, K.A., Armstrong, S.J., Barnes, K.B., Davies, C., Wong, J.P., Blanchard, J.D., Harding, S.V., Simpson, A.J. and H.S. Atkins. Liposome encapsulation of ciprofloxacin improves protection against highly virulent *Francisella tularensis* strain Schu S4. *Antimicrobial Agents and Chemotherapy* 58(6):3053-3059, 2014.
13. Hamblin, K.A, Wong, J.P., Blanchard, J.D and H.S. Atkins. The potential of liposome-encapsulated ciprofloxacin as a tularemia therapy. *Frontiers Cell. Infect. Microbiol.* 4:79 (doi:10:3389/fcimb.2014.00079), 2014.
14. Li, Y., Hu, Y., Zhang, G., Wong, J.P., Sun, L.Q., and M. Wang. Prophylactic, therapeutic and immune enhancement effect of LE-Poly ICLC on highly pathogenic H5N1 influenza virus infection. *Journal of Gene Medicine* 13(1):60-72, 2011.
15. Wong, J.P. Innovative drug designs using nucleic acid-recognizing toll-like receptor signalling pathways against virus infections. *International Journal of Molecular Sciences* (invited expert review paper in special issue), 2010.
16. M.E. Christopher, and J.P. Wong. Use of toll-like receptor 3 agonists against respiratory virus infections. *Anti-inflammatory and anti-Allergy Agents in Medicinal Chemistry*, 10:327-338, 2011.
17. Wong, J.P., Christopher, M.E., Viswanathan, S., Dai, X, Salazar, A.M., Sun, L.Q. and M. Wang. Antiviral role of toll-like receptor-3 agonists against seasonal and avian influenza influenza viruses. *Current Pharmaceutical Design* 15:1269-1274, 2009.